Trials / Withdrawn
WithdrawnNCT01652261
Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)
Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lymphoma, a Randomized Phase III Non-inferiority Study of the EORTC Lymphoma Group
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the trial is to show that doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-based response-adapted therapy for advanced-stage Hodgkin lymphoma, with treatment intensification (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) in case of a positive fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) after one cycle of ABVD, has non-inferior efficacy compared with the intensive BEACOPPesc regimen. A second objective is to assess the prognostic value of FDG-PET/CT after one cycle of BEACOPPesc.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABVD + FDG-PET/CT Scan treatment adaptation | |
| DRUG | BEACOPPesc |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2012-07-30
- Last updated
- 2021-02-15
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01652261. Inclusion in this directory is not an endorsement.